Guided Therapeutics, Inc.
GTHP
$0.20
-$0.03-12.28%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 883.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 883.33% | |||
| Cost of Revenue | -- | 428.00% | |||
| Gross Profit | -- | 1,208.57% | |||
| SG&A Expenses | -63.86% | 241.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -80.77% | 188.15% | |||
| Operating Income | 69.20% | -102.14% | |||
| Income Before Tax | 58.95% | -64.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 58.95% | -64.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 58.95% | -64.15% | |||
| EBIT | 69.20% | -102.14% | |||
| EBITDA | 69.31% | -102.36% | |||
| EPS Basic | 22.45% | -53.13% | |||
| Normalized Basic EPS | 61.54% | -82.00% | |||
| EPS Diluted | 22.45% | -47.00% | |||
| Normalized Diluted EPS | 61.54% | -82.00% | |||
| Average Basic Shares Outstanding | 5.01% | 3.56% | |||
| Average Diluted Shares Outstanding | 5.01% | 3.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||